Collaboration agreement contingent consideration potential cash payment.

No definition available.

Name:	cris_CollaborationAgreementContingentConsiderationPotentialCashPayment
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration agreement contingent consideration received from partner.

+ References

No definition available.

+ Details

Name:	cris_CollaborationAgreementContingentConsiderationReceivedFromPartner
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Common stock issued one time issuance to university licenses number.

+ References

No definition available.

+ Details

Name:	cris_CommonStockIssuedOneTimeIssuanceToUniversityLicensesNumber
Namespace Prefix:	cris_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent obligations.

+ References

No definition available.

+ Details

Name:	cris_ContingentObligations
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contra Revenues

+ References

No definition available.

+ Details

Name:	cris_ContraRevenues
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Payments Received From Partner

+ References

No definition available.

+ Details

Name:	cris_MilestonePaymentsReceivedFromPartner
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestones recognized from partner.

+ References

No definition available.

+ Details

Name:	cris_MilestonesRecognizedFromPartner
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Obligation limit.

+ References

No definition available.

+ Details

Name:	cris_ObligationLimit
Namespace Prefix:	cris_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Royalty Rate Of Net Sales

+ References

No definition available.

+ Details

Name:	cris_PercentageOfRoyaltyRateOfNetSales
Namespace Prefix:	cris_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of sublicense fees paid on royalties earned.

+ References

No definition available.

+ Details

Name:	cris_PercentageOfSublicenseFeesPaidOnRoyaltiesEarned
Namespace Prefix:	cris_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds from contribution of fund.

+ References

No definition available.

+ Details

Name:	cris_ProceedsFromContributionOfFund
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Reduced Royalty Rate

+ References

No definition available.

+ Details

Name:	cris_ReducedRoyaltyRate
Namespace Prefix:	cris_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Historically, this has included FTE reimbursement. It also includes reimbursement of other costs that have been incurred on behalf of a partner.

+ References

No definition available.

+ Details

Name:	cris_ResearchAndDevelopmentRevenue
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue recognized milestone achieved upon treatment of first patient of phase one trial.

+ References

No definition available.

+ Details

Name:	cris_RevenueRecognizedMilestoneAchievedUponTreatmentOfFirstPatientOfPhaseOneTrial
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty Percentage

+ References

No definition available.

+ Details

Name:	cris_RoyaltyPercentage
Namespace Prefix:	cris_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty portion of annual worldwide net sales amount.

+ References

No definition available.

+ Details

Name:	cris_RoyaltyPortionOfAnnualWorldwideNetSalesAmount
Namespace Prefix:	cris_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaboration Agreements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended			1 Months Ended	3 Months Ended		9 Months Ended			1 Months Ended	3 Months Ended	9 Months Ended				1 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	May 31, 2013 Genentech Inc [Member]	Sep. 30, 2014 Genentech Inc [Member]	Sep. 30, 2013 Genentech Inc [Member]	Sep. 30, 2014 Genentech Inc [Member] Licensors	Sep. 30, 2013 Genentech Inc [Member]	Jun. 30, 2014 Genentech Inc [Member]	Nov. 30, 2011 Leukemia and Lymphoma Society [Member]	Sep. 30, 2014 Leukemia and Lymphoma Society [Member]	Sep. 30, 2014 Leukemia and Lymphoma Society [Member]	Sep. 30, 2013 Leukemia and Lymphoma Society [Member]	Sep. 30, 2014 Minimum [Member] Genentech Inc [Member]	Sep. 30, 2014 Maximum [Member] Genentech Inc [Member]	Nov. 30, 2011 Maximum [Member] Leukemia and Lymphoma Society [Member]	Sep. 30, 2014 Maximum [Member] Leukemia and Lymphoma Society [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Earned milestone payment									$ 3,000,000			$ 1,650,000			$ 650,000
Eligibility to receive contingent cash milestone payments under the collaboration							115,000,000		115,000,000
Earned milestone payment						4,000,000
Amount earned for specified clinical development and regulatory objectives							59,000,000		59,000,000
License fees	0	6,000,000	3,000,000	10,000,000				6,000,000	3,000,000	10,000,000
Milestone amounts included accounts receivable	1,839,319		1,839,319		1,477,188						3,000,000
Number of university licensors in connection with the FDA-approval of Erivedge									2
Research and development expenses	3,705,365	4,170,751	10,180,271	9,965,847				300,000	150,000	500,000
Percentage of royalty rate escalation																5.00%	7.50%
Royalty portion of annual worldwide net sales																150,000,000	600,000,000
Percentage of royalty rate decrease									2.00%
Percentage of royalty																3.00%	5.50%
Recognized royalty revenues	1,783,271	1,080,233	4,895,454	2,549,945			1,783,271	1,080,233	4,895,454	2,549,945
Costs of royalty revenues recorded	89,295	54,014	246,280	127,499			89,295	54,014	246,280	127,499
Percentage of royalties earned							5.00%	5.00%	5.00%	5.00%
Research and development revenue	(18,407)	121,850	(44,672)	927,950			72,817	87,916	144,054	181,910
Contra-revenues							94,118		233,701
Contribution of fund from LLS amount																		4,000,000
Revenue recognized, milestone achieved upon treatment of first patient of phase one trial													0	0	650,000
Royalty obligation on successful progressing of CUDC - 907 through clinical trials														$ 4,125,000					$ 10,000,000
Multiplier applied to milestone payments received to determine royalty obligation														2.5